Flatiron Health

Flatiron Health is a healthtech company focused on oncology data, intelligence and technology. It combines AI-powered technology, clinical expertise and real-world oncology data to support both healthcare providers and life sciences organizations. Its "global oncology engine" is built on one of the largest oncology datasets spanning the United States, United Kingdom, Germany and Japan, and is paired with point-of-care software used by community oncologists in the US.

The company operates two principal lines of solutions. For the point of care, it provides oncology-specific software, including the OncoEMR electronic medical record (acquired with Altos Solutions in 2014), and historically OncoAnalytics analytics, OncoBilling practice management and the SeeYourChart patient portal under the OncologyCloud/OncoCloud platform. For life sciences, it offers Flatiron Real-World Data, Real-World Evidence Insights advisory and analytics, and Flatiron Telescope, an AI platform that uses natural language querying to interrogate Flatiron datasets. Use cases span clinical development (natural history, biomarker testing strategy, target product profile design, trial design, predictive modeling and digital twins), HEOR/RWE, market access and HTA submissions, regulatory interactions, and commercial analytics.

Flatiron states that its real-world data has informed more than 2,000 peer-reviewed publications, that it has 5M+ patient records covering the four largest cancer geographies, that its evidence has informed 45+ global regulatory decisions, and that 100% of the top 20 oncology life sciences companies partner with the company. It also reports partnerships with the National Cancer Institute, the U.S. Food & Drug Administration and the National Comprehensive Cancer Network, and founding membership of the RWE Alliance.

Founding story

Flatiron Health was founded in 2012 by Nat Turner and Zach Weinberg after they witnessed several family members and friends battle cancer. Observing that physicians were increasingly documenting care electronically but lacked advanced analytics and decision-support tools, they set out to build a software platform to make that data usable at scale. Google had acquired their previous company, Invite Media, in 2010.

Business model

Flatiron sells oncology software and data/analytics services. Cancer care providers use its point-of-care technology (notably the OncoEMR electronic medical record, plus practice management, billing, patient portal and analytics tools), while life sciences organizations purchase real-world data, evidence-generation services and AI-based analytics platforms derived from de-identified patient records collected across its provider network.

Sources describe commercial offerings to two customer groups — provider-facing software products and life science data/evidence offerings purchased by pharmaceutical companies (for example, Roche agreed in 2016 to a multi-year, non-exclusive agreement to purchase a number of Flatiron's life science offerings) — but do not disclose pricing structures or revenue figures.

Traction

Reported metrics include 5M+ patient records (life sciences page) and more than 3 million patient records available for research in its network (75% community, 25% academic), 280+ community cancer centers and eight major academic cancer centers, 20+ top global oncology therapeutics developers, 2,000+ peer-reviewed publications, 45+ global regulatory decisions informed, and 2,500+ employees. At the time of the 2014 Altos acquisition, Altos software was used by over 1,300 oncology clinicians whose physicians saw over 550,000 unique cancer patients annually.

Latest developments

In July 2026 Flatiron announced its first partnership in Scotland, described as a nearly 70% expansion of its global network, and Quest Diagnostics became the largest clinical reference lab to extend oncology test access through OncoEMR MPI, with American Oncology Network and other community providers launching in a pilot providing access to Haystack MRD. In August 2026 the company announced three research acceptances at WCLC 2026, and it has multiple abstracts accepted for ASCO in May 2026.